Nasdaq:US$15.81 (+0.12) | HKEX:HK$24.60 (-0.60) | AIM:£2.30 (+0.09)
Search
News & Press Releases
123456
7
89
found Documents: 430
Announcements & Press Releases, Group | 2 Aug 2016

Change of Non-executive Directors
London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 2 Aug 2016

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment.   Innovation Platform – Seven drug candidates in 25
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Aug 2016

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program
First global pivotal Phase III in c-Met-driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near future London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 glo
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 5 Jul 2016

Chi-Med to Announce 2016 Half-Year Financial Results
London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jun 2016

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-am
Read More
Savolitinib Clinical Trials Summary (PDF)View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 May 2016

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer
London: Friday, May 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced
Read More
View Announcement (PDF)
Group, Press Releases | 4 May 2016

Chi-Med to Participate in Two Healthcare Investor Conferences in May
London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May. Conference Details: E
Read More
Announcements & Press Releases, Group | 13 Apr 2016

Hutchison China MediTech Limited Announces Exercise of Overallotment Option
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Apr 2016

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli
Read More
View Announcement (PDF)
Announcements & Press Releases, Group, Press Releases | 22 Mar 2016

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)View Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Mar 2016

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients
London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 18 Mar 2016

Final Prospectus
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 17 Mar 2016

Pricing of U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONS
Read More
View Announcement (PDF)
Announcements & Press Releases, Group, Press Coverage | 17 Mar 2016

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs
Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 15 Mar 2016

2015 Annual Report and Notice of Annual General Meeting
London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 7 Mar 2016

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 4 Mar 2016

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs
Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 4 Mar 2016

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 Mar 2016

Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer
London: Wednesday, 2 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated an open-label Phase II clinical trial to evaluate t
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 1 Mar 2016

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Full Announcement (PDF)
Announcements & Press Releases, Group | 1 Mar 2016

Final Results for the year ended 31 December 2015
Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III
Read More
View Full Announcement (PDF)View Announcement Summary (PDF)View Chairman's Statement (PDF)View Operations Review (PDF)View Financial Statements (PDF)
Announcements & Press Releases, Group | 11 Feb 2016

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Jan 2016

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia
London: Friday, 15 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with haema
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Dec 2015

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients
London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 9 Dec 2015

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Dec 2015

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer
London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 13 Nov 2015

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
View Full Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Nov 2015

Chi-Med initiates sulfatinib U.S. clinical trials
London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 30 Oct 2015

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Oct 2015

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers
London:  Friday, 30 October 2015:  Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Oct 2015

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
Read More
View Announcement (PDF)
Announcements & Press Releases, Group, Press Releases | 16 Oct 2015

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing
Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 16 Oct 2015

Shareholders' Circular and Notice of Extraordinary General Meeting
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 16 Oct 2015

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Oct 2015

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
Read More
View PDF
Announcements & Press Releases, Group | 8 Oct 2015

Winner of International Company of the Year 2015, AIM
At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners
Read More
Announcements & Press Releases, Oncology / Immunology | 14 Sep 2015

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress
London: Monday, 14 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present the detailed clinical results of its Phase II proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 2 Sep 2015

Second proof-of-concept trial of fruquintinib achieves its primary endpoint
London: Wednesday, 2 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 19 Aug 2015

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project
London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of
Read More
View PDF
Announcements & Press Releases, Group | 28 Jul 2015

Interim Results for the Six Months Ended 30 June 2015
For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
Read More
PDF
Announcements & Press Releases, Other Ventures | 17 Jul 2015

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
Read More
a150717
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2015

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting
London: Monday, 1 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM), today announces that AstraZeneca AB (publ) (“AstraZeneca”), Hutchison MediPharma Limited’s (“HMP”) collaboration partner, presented preliminary data f
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 May 2015

Positive fruquintinib proof-of-concept study results trigger payments from Lilly
London: Wednesday, 13 May 2015: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, is set to receive a total of US$18 million in payments, in the second quarter of 2015, from Eli Lilly and
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Mar 2015

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint
London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in pati
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Mar 2015

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer
London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 26 Feb 2015

Final Results for the year ended 31 December 2014
For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 29 Jan 2015

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China
Press Release -  London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Dec 2014

Initiation of fruquintinib Phase III registration study in colorectal cancer
London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer (“CRC”) patients in China, for
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 7 Oct 2014

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014
Press Release -  London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o
Read More
View Announcement (PDF)
123456
7
89